Product image of Lenvima (Lenvatinib) supplied by GNH India

Lenvima

Active Ingredient:
Lenvatinib
Origin:
EU

Lenvima (Lenvatinib)

lenvatinib, the active ingredient in Lenvima, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for several advanced solid tumours and is prescribed by oncologists for adult patients with specific cancer types.
GNH India supplies Lenvima as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eisai Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenvima targets multiple signalling pathways that drive tumour growth and angiogenesis, making it useful in several solid‑tumour indications.

  • Differentiated thyroid carcinoma: helps control disease progression in patients with radioactive iodine‑refractory disease.
  • Renal cell carcinoma: used in combination with everolimus to improve progression‑free survival.
  • Hepatocellular carcinoma: administered as first‑line therapy for unresectable disease.
  • Endometrial carcinoma: combined with pembrolizumab for advanced or recurrent cases.

How It Works

  • Lenvatinib inhibits a spectrum of receptor tyrosine kinases, including VEGFR 1‑3, FGFR 1‑4, PDGFRα, RET and KIT. By blocking these receptors, it reduces tumour angiogenesis, limits proliferative signalling, and impairs cancer cell survival, thereby slowing tumour growth and spread.

Side Effects

Lenvima may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

  • Hypertension: elevated blood pressure requiring monitoring.
  • Diarrhoea: may be mild to moderate.
  • Fatigue: persistent tiredness.
  • Nausea: occasional upset stomach.
  • Decreased appetite: reduced food intake.
  • Proteinuria: presence of protein in urine.

Serious or Rare Side Effects

  • Hepatotoxicity: liver enzyme elevations or failure.
  • Cardiac dysfunction: reduced left‑ventricular ejection fraction.
  • Thromboembolic events: blood clots in veins or arteries.
  • Gastrointestinal perforation: rare but severe bowel injury.
  • Severe haemorrhage: uncontrolled bleeding.
  • Renal failure: impaired kidney function.

Precautions & Warnings

Before initiating Lenvima, clinicians should assess patient risk factors and monitor relevant parameters.

  • Blood pressure monitoring: check regularly and treat hypertension promptly.
  • Liver function tests: evaluate baseline and periodic hepatic enzymes.
  • Cardiac assessment: perform echocardiogram if history of heart disease.
  • Pregnancy risk: avoid use in pregnancy; discuss contraception.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Avoid Interactions

Lenvima can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenvatinib exposure.
  • Anticoagulants (e.g., warfarin): heightened risk of bleeding.
  • High‑dose aspirin or NSAIDs: increased gastrointestinal bleeding risk.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): may reduce drug levels.
  • Diuretics: may exacerbate hypertension.
  • Hormonal contraceptives: potential reduced effectiveness.

Frequently Asked Questions

Lenvima (lenvatinib) is prescribed for adult patients with differentiated thyroid carcinoma that is refractory to radioactive iodine, advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and advanced or recurrent endometrial carcinoma, often in combination with other targeted agents.

Lenvatinib blocks multiple receptor tyrosine kinases such as VEGFR, FGFR, PDGFRα, RET and KIT. Inhibiting these pathways reduces tumour blood‑vessel formation, slows cell proliferation, and promotes cancer cell death, thereby limiting tumour growth.

The specific dose of Lenvima is determined by the treating physician based on the patient’s cancer type, disease stage, renal and hepatic function, and other clinical factors. Patients should follow the prescribing information provided by their healthcare professional.

Lenvima is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and effective contraception is required. Safety during breastfeeding has not been established, so breastfeeding is generally discouraged while on therapy.

To request Lenvima, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenvima uniquely targets both VEGFR and FGFR families, offering broader inhibition of angiogenic pathways compared with some TKIs that focus mainly on VEGFR. This broader spectrum can be advantageous in tumours driven by multiple growth factors, though safety profiles differ and should be evaluated individually.

Lenvima tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Lenvima is taken orally as a tablet, usually once daily on an empty stomach (at least one hour before or two hours after a meal). Patients should swallow the tablet whole with water and follow any specific instructions from their prescriber.

Serious risks include severe hypertension, liver toxicity, cardiac dysfunction, thromboembolic events, gastrointestinal perforation, and severe bleeding. Patients should be monitored regularly for these events, and therapy should be adjusted or discontinued if serious adverse reactions occur.

Lenvima is contraindicated in patients with known hypersensitivity to lenvatinib or any of its excipients. It should also be avoided in pregnant women and used with caution in patients with uncontrolled hypertension, significant liver impairment, or severe cardiac disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenvatinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT